Huron Consulting replaces Supernus Pharmaceuticals in S&P SmallCap 600 on Nov 3 after merger delays.

Huron Consulting Group will join the S&P SmallCap 600 index on November 3, replacing Supernus Pharmaceuticals. The change was delayed from November 2 due to a special dividend related to Supernus' acquisition by Indivior Pharmaceuticals. After the merger, Indivior will rename itself Supernus Inc. and continue trading under the SUPN ticker, remaining in the index. This update reflects ongoing corporate restructuring impacting the index composition.

As of Oct 29, 2026 05:01 WIB, Indivior Pharmaceuticals Inc. Common Stock (INDV) trades at USD 34.78 with a slight 1-day increase of 0.17% on Pluang. The stock shows strong buying interest with 100% buy orders and a market cap of $4.10 billion. This reflects steady investor confidence ahead of the corporate changes involving Supernus Pharmaceuticals and Indivior's upcoming rebranding.